See more : Solaria Energía y Medio Ambiente, S.A. (SLR.MC) Income Statement Analysis – Financial Results
Complete financial analysis of Monopar Therapeutics Inc. (MNPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Monopar Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Anhui Guofeng New Materials Co., Ltd. (000859.SZ) Income Statement Analysis – Financial Results
- Tailwind International Acquisition Corp. (TWNIF) Income Statement Analysis – Financial Results
- Zodiac-JRD-MKJ Limited (ZODJRDMKJ.NS) Income Statement Analysis – Financial Results
- Bank of Ayudhya Public Company Limited (BKAYY) Income Statement Analysis – Financial Results
- New Relic, Inc. (0K79.L) Income Statement Analysis – Financial Results
Monopar Therapeutics Inc. (MNPR)
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.60M | 7.59M | 6.49M | 4.07M | 1.97M | 1.77M | 15.44M | 280.36K | 101.49K |
| General & Administrative | 3.23M | 2.95M | 2.63M | 2.44M | 2.36M | 1.63M | 1.17M | 912.47K | 587.08K |
| Selling & Marketing | -3.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.23M | 2.95M | 2.63M | 2.44M | 2.36M | 1.63M | 1.17M | 912.47K | 587.08K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.50M | 0.00 | 0.00 |
| Operating Expenses | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.40M | 16.60M | 1.19M | 688.56K |
| Cost & Expenses | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.40M | 16.60M | 1.19M | 688.56K |
| Interest Income | 429.04M | 21.24K | 24.02K | 81.90K | 98.89K | 103.22K | 48.26K | 7.23K | 1.25K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103.22K | 48.26K | 7.23K | 0.00 |
| Depreciation & Amortization | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.33M | 2.10M | 1.19M | 688.56K |
| EBITDA | 429.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -16.55M | 8.03K | 1.25K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.83M | -10.54M | -9.13M | -6.51M | -4.32M | -3.40M | -16.60M | -1.19M | -688.56K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 429.04K | 21.24K | 24.02K | 204.30K | 98.89K | 31.15K | 48.26K | 8.03K | 1.25K |
| Income Before Tax | -8.40M | -10.52M | -9.10M | -6.30M | -4.22M | -3.30M | -16.55M | -1.19M | -687.31K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -21.24K | -24.02K | -81.90K | -98.89K | -71.62K | -2.10M | 800.00 | -688.56K |
| Net Income | -8.40M | -10.49M | -9.08M | -6.22M | -4.13M | -3.23M | -16.55M | -1.19M | -687.31K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.58 | -0.83 | -0.73 | -0.57 | -0.39 | -0.31 | -1.59 | -0.11 | -0.06 |
| EPS Diluted | -0.58 | -0.83 | -0.73 | -0.57 | -0.39 | -0.31 | -1.59 | -0.11 | -0.06 |
| Weighted Avg Shares Out | 14.51M | 12.72M | 12.47M | 10.96M | 10.59M | 10.42M | 10.42M | 10.42M | 10.59M |
| Weighted Avg Shares Out (Dil) | 14.51M | 12.72M | 12.47M | 10.96M | 10.59M | 10.42M | 10.42M | 10.42M | 10.59M |
Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones
Monopar Therapeutics Is Trading Higher On Announcing Its uPA Radiotracer Along With Pet Imaging Can Detect Breast Cancer
MNPR Stock Price Increased Over 15% Pre-Market: Why It Happened
Monopar's uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates
Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery
Monopar Therapeutics to Present at Upcoming Investor Conferences
Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
MNPR Stock Price Increases Over 30% Pre-Market: Why It Happened
Source: https://incomestatements.info
Category: Stock Reports